Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials
Rudwaleit M, Brown MA, Van Gaalen F, Haroon N, Gensler L, Fleurinck C, Marten A, Massow U, De Peyrecave N, Vaux T, White K, et al. (2023)
In: Abstract Supplement ACR Convergence 2023. Arthritis & Rheumatology, 75(Suppl. 9). Hoboken: Wiley: 5060-5062.
Kurzbeitrag Konferenz / Poster
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Rudwaleit, MartinUniBi;
Brown, Matthew A.;
Van Gaalen, Floris;
Haroon, Nigil;
Gensler, Lianne;
Fleurinck, Carmen;
Marten, Alexander;
Massow, Ute;
De Peyrecave, Natasha;
Vaux, Thomas;
White, Katy;
Deodhar, Atul
Alle
Alle
Einrichtung
Erscheinungsjahr
2023
Titel des Konferenzbandes
Abstract Supplement ACR Convergence 2023
Serien- oder Zeitschriftentitel
Arthritis & Rheumatology
Band
75
Ausgabe
Suppl. 9
Seite(n)
5060-5062
Konferenz
ACR Convergence 2023
Konferenzort
San Diego, CA
Konferenzdatum
2023-11-10 – 2023-11-15
ISSN
2326-5191
eISSN
2326-5205
Page URI
https://pub.uni-bielefeld.de/record/2993460
Zitieren
Rudwaleit M, Brown MA, Van Gaalen F, et al. Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials. In: Abstract Supplement ACR Convergence 2023. Arthritis & Rheumatology. Vol 75. Hoboken: Wiley; 2023: 5060-5062.
Rudwaleit, M., Brown, M. A., Van Gaalen, F., Haroon, N., Gensler, L., Fleurinck, C., Marten, A., et al. (2023). Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials. Abstract Supplement ACR Convergence 2023, Arthritis & Rheumatology, 75, 5060-5062. Hoboken: Wiley. https://doi.org/10.1002/art.42700
Rudwaleit, Martin, Brown, Matthew A., Van Gaalen, Floris, Haroon, Nigil, Gensler, Lianne, Fleurinck, Carmen, Marten, Alexander, et al. 2023. “Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials”. In Abstract Supplement ACR Convergence 2023, 75:5060-5062. Arthritis & Rheumatology. Hoboken: Wiley.
Rudwaleit, M., Brown, M. A., Van Gaalen, F., Haroon, N., Gensler, L., Fleurinck, C., Marten, A., Massow, U., De Peyrecave, N., Vaux, T., et al. (2023). “Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials” in Abstract Supplement ACR Convergence 2023 Arthritis & Rheumatology, vol. 75, (Hoboken: Wiley), 5060-5062.
Rudwaleit, M., et al., 2023. Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials. In Abstract Supplement ACR Convergence 2023. Arthritis & Rheumatology. no.75 Hoboken: Wiley, pp. 5060-5062.
M. Rudwaleit, et al., “Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials”, Abstract Supplement ACR Convergence 2023, Arthritis & Rheumatology, vol. 75, Hoboken: Wiley, 2023, pp.5060-5062.
Rudwaleit, M., Brown, M.A., Van Gaalen, F., Haroon, N., Gensler, L., Fleurinck, C., Marten, A., Massow, U., De Peyrecave, N., Vaux, T., White, K., Deodhar, A., van der Horst-Bruinsma, I.: Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials. Abstract Supplement ACR Convergence 2023. Arthritis & Rheumatology. 75, p. 5060-5062. Wiley, Hoboken (2023).
Rudwaleit, Martin, Brown, Matthew A., Van Gaalen, Floris, Haroon, Nigil, Gensler, Lianne, Fleurinck, Carmen, Marten, Alexander, Massow, Ute, De Peyrecave, Natasha, Vaux, Thomas, White, Katy, Deodhar, Atul, and van der Horst-Bruinsma, Irene. “Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials”. Abstract Supplement ACR Convergence 2023. Hoboken: Wiley, 2023.Vol. 75. Arthritis & Rheumatology. 5060-5062.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Suchen in
Google Scholar